These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 19224848

  • 1. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L.
    J Clin Oncol; 2009 Mar 20; 27(9):1426-31. PubMed ID: 19224848
    [Abstract] [Full Text] [Related]

  • 2. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group Study.
    Gynecol Oncol; 2008 Dec 20; 111(3):455-60. PubMed ID: 18829087
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D.
    J Clin Oncol; 2004 Nov 15; 22(22):4523-31. PubMed ID: 15542803
    [Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 15; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A, Blessing J, Bender D, Mannel R, Morgan M, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar 15; 100(3):586-90. PubMed ID: 16249022
    [Abstract] [Full Text] [Related]

  • 9. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT.
    Clin Cancer Res; 1996 Oct 15; 2(10):1693-7. PubMed ID: 9816118
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan 15; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.
    Gynecol Oncol; 2004 Dec 15; 95(3):686-90. PubMed ID: 15581982
    [Abstract] [Full Text] [Related]

  • 16. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 15; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 17. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M.
    Gynecol Oncol; 2000 Nov 15; 79(2):211-5. PubMed ID: 11063646
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS.
    Gynecol Oncol; 2011 Jul 15; 122(1):111-5. PubMed ID: 21497382
    [Abstract] [Full Text] [Related]

  • 20. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
    Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ.
    Gynecol Oncol; 2010 Oct 15; 119(1):32-7. PubMed ID: 20584542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.